-transparent.png){kind=logo}
The disposition of 1-alpha-acetylmethadol (LAAM) in plasma and urine was monitored by GC/CIMS following oral administration of 10 doses (0.73-1.5 mg/kg) over 42 days, to twelve human subjects. Plasma concentration-time course profiles fitted a two-compartment, first order kinetic model. Mean plasma t1/2 alpha for LAAM was 2.4 hours; t1/2 beta was 37.5 hours for the first dose and 46.8 hours for the last dose. The mean terminal half-life for nor-LAAM was 38.2 hours for first and 64.6 for last dose; for dinor-LAAM t1/2 beta was 168 hours, last dose. Drug accumulation occurred in some subjects, but within the study range, dosage was not related to maximum plasma levels nor to accumulation. In urine, the sum of LAAM, nor-LAAM, and dinor-LAAM represented 25% of the dose, and unconjugated methadol metabolites, 1.6-1.7%.
B S Finkle, and
T A Jennison, and
D M Chinn, and
W Ling, and
E D Holmes
July 1980,
Biochemical pharmacology,
B S Finkle, and
T A Jennison, and
D M Chinn, and
W Ling, and
E D Holmes
July 1974,
Research communications in chemical pathology and pharmacology,
B S Finkle, and
T A Jennison, and
D M Chinn, and
W Ling, and
E D Holmes
May 1984,
Clinical chemistry,
B S Finkle, and
T A Jennison, and
D M Chinn, and
W Ling, and
E D Holmes
April 1979,
Pharmacology, biochemistry, and behavior,
B S Finkle, and
T A Jennison, and
D M Chinn, and
W Ling, and
E D Holmes
January 1983,
The Journal of pharmacology and experimental therapeutics,
B S Finkle, and
T A Jennison, and
D M Chinn, and
W Ling, and
E D Holmes
March 1985,
Journal of pharmaceutical sciences,
B S Finkle, and
T A Jennison, and
D M Chinn, and
W Ling, and
E D Holmes
January 1999,
Journal of pharmaceutical and biomedical analysis,
B S Finkle, and
T A Jennison, and
D M Chinn, and
W Ling, and
E D Holmes
July 1976,
NIDA research monograph,
B S Finkle, and
T A Jennison, and
D M Chinn, and
W Ling, and
E D Holmes
June 2004,
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences,
B S Finkle, and
T A Jennison, and
D M Chinn, and
W Ling, and
E D Holmes
January 1980,
Biopharmaceutics & drug disposition,
